In Vivo Evidence of Human Organic Anion Transporting Polypeptide ( OATP ) 1B1 and OATP1B3 Mediated Disposition of Glycyrrhizin and Its Drug–Drug Interactions in Humanized Mice
Authors:
- 10 June 2026
- journal article
- Published by Wiley in Phytotherapy Research
- Vol. 40 (9) , 5405-5419
Abstract
Organic anion‐transporting polypeptide (OATP) transporters have a significant influence on the disposition of drugs, significantly influencing their efficacy and toxicity. Humans express two transporters (OATP1B1 and OATP1B3), while murine possess only a single ortholog (Oatp1b2). To elucidate the impact of OATP1B1 and 1B3 on the pharmacokinetics of the hepatoprotective agent glycyrrhizin and its potential drug–drug interactions, we conducted a study utilizing wild‐type, murine Oatp1b2 knockout, and newly generated humanized OATP1B1 and OATP1B3 transgenic mice ( Slco1b2 −/− ; 1B1/1B3 tg ). These models were characterized physiologically and biochemically, followed by intravenous administration of glycyrrhizin for pharmacokinetic analysis. Compared to wild‐type controls, Oatp1b2 knockout mice exhibited a 2‐fold decrease in liver AUC 0–7h and up to 26.9‐fold reduction in liver‐to‐plasma ratios, indicating impaired hepatic uptake of glycyrrhizin. Additionally, the absence of Oatp1b2 resulted in a 2.8‐fold increase in plasma AUC 0–7h and enhanced renal distribution of glycyrrhizin. However, the knock‐in of human OATP1B1 and OATP1B3 partially or fully restored the impaired hepatic uptake and reduced plasma levels of glycyrrhizin in Oatp1b2 knockout mice. Furthermore, we evaluated drug–drug interactions between glycyrrhizin and glecaprevir/pibrentasvir, a clinically relevant combination. Glecaprevir/pibrentasvir inhibited OATP1B1/1B3‐mediated hepatic uptake of glycyrrhizin at therapeutic concentrations, increasing systemic exposure and highlighting drug–drug interaction risks. Our study provides the first in vivo evidence of glycyrrhizin hepatic transport by human OATP1B1 and OATP1B3, emphasizing the need for careful dosing in patients with variable OATP1B/1B3 activity due to transporter‐mediated drug–drug interactions. Additionally, this humanized mouse model can serve as a robust in vivo tool for the prediction of human OATP1B1 and 1B3 function.Keywords
Funding Information
- National Natural Science Foundation of China (82104700)
- Jiangsu Commission of Health (Z2025066)
This publication has 27 references indexed in Scilit:
- Glycyrrhizin-Induced Pseudohyperaldosteronism: A Case ReportChinese Journal of Integrative Medicine, 2022
- Importance of Hepatic Transporters in Clinical Disposition of Drugs and Their MetabolitesThe Journal of Clinical Pharmacology, 2016
- Adverse Effects of Plant Food Supplements and Plants Consumed as Food: Results from the Poisons Centres-Based PlantLIBRA StudyPhytotherapy Research, 2016
- Drug Interactions Between Hepatoprotective Agents Ursodeoxycholic Acid or Glycyrrhizin and Ombitasvir/Paritaprevir/Ritonavir in Healthy Japanese SubjectsClinical Therapeutics, 2015
- In vivodisposition of doxorubicin is affected by mouse Oatp1a/1b and human OATP1A/1B transportersInternational Journal of Cancer, 2014
- Targeted Metabolomic Study Indicating Glycyrrhizin's Protection against Acetaminophen‐induced Liver Damage through Reversing Fatty Acid MetabolismPhytotherapy Research, 2013
- Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorptionBiopharmaceutics & Drug Disposition, 2013
- Review of Pharmacological Effects of Glycyrrhiza sp. and its Bioactive CompoundsPhytotherapy Research, 2008
- Pharmacokinetic profiles of glycyrrhizin in patients with chronic hepatitisBiopharmaceutics & Drug Disposition, 1993
- Pharmacokinetic profile of glycyrrhizin in healthy volunteers by a new high‐performance liquid chromatographic methodJournal of Pharmaceutical Sciences, 1992